Office for Technology Commercialization

Potent HIV Integrase Inhibitor

Technology #20150106

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
HIV StructureHIV IntegraseHIV Integrase Inhibitor
Zhengqiang Wang, PhD
Associate Professor, Center for Drug Design (CDD)
External Link (
Managed By
Larry Micek
Technology Licensing Officer 612-624-9568
Patent Protection

US Patent Pending

Integrase Strand Transfer Inhibitor

A next generation HIV integrase strand transfer (INST) inhibitor selectively targets and potently inhibits HIV integrase. The drug features a distinct pharmacophore and shows great promise in reducing resistance. Biochemical testing and molecular modeling strongly corroborate the inhibition of INST as the antiviral mechanism of action. Furthermore, selected antiviral analogues also potently inhibited reverse transcriptase (RT) associated RNase H, implying potential dual target inhibition.

May Target Drug-Resistant HIV

HIV integrase is a validated target that catalyzes the integration of viral genetic material into a host genome. Current integrase inhibitors primarily interfere with the strand transfer process, but this compound has a significantly different structure than known HIV inhibitors. In fact, this inhibitor may even effectively target drug-resistant strains of HIV.


  • Selectively targets and potently inhibits HIV integrase
  • Dual target inhibition: also inhibits reverse transcriptase (RT) associated RNase H
  • Shows promise in reducing drug resistance
  • Distinct 3-hydroxypyrimidine-2,4-dione core


  • HIV integrase inhibitor combined with other antiretroviral drugs
  • Empower other non-integrase inhibitor lead candidates
  • Potently inhibit reverse transcriptase (RT) associated RNase H as well

Phase of Development In Vitro assessment; In Vivo/animal studies